Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

Axsome Therapeutics (AXSM) reported strong first-half 2026 results with its lead drug Auvelity generating $333 million in sales, up 54.2% year-over-year. The company is expanding Auvelity's market reach through FDA approval for Alzheimer's agitation treatment and a phase III smoking cessation study. Additional revenue support comes from Sunosi ($66.5M sales) and newly launched Symbravo ($6.3M sales), though the company faces intense competition in the CNS and migraine markets.